{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:36:29Z","timestamp":1780554989091,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["APP1034300"],"award-info":[{"award-number":["APP1034300"]}]},{"name":"Australian National Health and Medical Research Council","award":["1104299"],"award-info":[{"award-number":["1104299"]}]},{"name":"Bethlehem Griffith Research Foundation","award":["BGRF1501"],"award-info":[{"award-number":["BGRF1501"]}]},{"name":"Early Career Research grant","award":["704-6496"],"award-info":[{"award-number":["704-6496"]}]},{"name":"Stafford Fox Medical Research Foundation"},{"DOI":"10.13039\/100008714","name":"MND Research Institute of Australia","doi-asserted-by":"crossref","award":["1609"],"award-info":[{"award-number":["1609"]}],"id":[{"id":"10.13039\/100008714","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012257","name":"Cure for MND Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012257","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004752","name":"Victorian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuint.2017.02.016","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T20:07:55Z","timestamp":1491336475000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-8856","authenticated-orcid":false,"given":"Anna","family":"Farrelly-Rosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chew Ling","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazel","family":"Shabanpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2017.02.016_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in\u00a0vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib2","series-title":"SPINRAZA_READINESS","author":"Biogen","year":"2016"},{"key":"10.1016\/j.neuint.2017.02.016_bib3","volume":"vol. 26","author":"BIOGEN","year":"2016"},{"key":"10.1016\/j.neuint.2017.02.016_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2015.02.008","article-title":"Delivery of therapeutic oligonucleotides with cell penetrating peptides","volume":"87","author":"Boisgu\u00e9rin","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuint.2017.02.016_bib5","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In\u00a0vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2017.02.016_bib7","first-page":"597","article-title":"Spinal Muscular Atrophy: why do low levels of SMN make motor neurons sick? Nature reviews","volume":"10","author":"Burghes","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2017.02.016_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ng1195-335","article-title":"A\u00a0frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients","volume":"11","author":"Bussaglia","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.neuint.2017.02.016_bib10","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuint.2017.02.016_bib11","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.neuint.2017.02.016_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcn.2013.04.005","article-title":"Splicing therapy for neuromuscular disease","volume":"56","author":"Douglas","year":"2013","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neuint.2017.02.016_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuint.2017.02.016_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/dneu.22111","article-title":"Dynamics of survival of motor neuron (SMN) protein interaction with the mRNA-binding protein IMP1 facilitates its trafficking into motor neuron axons","volume":"74","author":"Fallini","year":"2014","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.neuint.2017.02.016_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.neuint.2017.02.016_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0959-437X(02)00301-5","article-title":"The molecular bases of spinal muscular atrophy","volume":"12","author":"Frugier","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.neuint.2017.02.016_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/hmg\/dds437","article-title":"VPA response in SMA is suppressed by the fatty acid translocase CD36","volume":"22","author":"Garbes","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2353\/ajpath.2009.080537","article-title":"Valproic acid activates the PI3K\/Akt\/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy","volume":"174","author":"Gurpur","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuint.2017.02.016_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In\u00a0vitro and ex\u00a0vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuint.2017.02.016_bib20","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuint.2017.02.016_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.braindev.2011.04.010","article-title":"Valproic acid increases SMN2 expression and modulates SF2\/ASF and hnRNPA1 expression in SMA fibroblast cell lines","volume":"34","author":"Harahap","year":"2012","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuint.2017.02.016_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuint.2017.02.016_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1476-5381.2011.01259.x","article-title":"The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes","volume":"163","author":"Lau","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2017.02.016_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2017.02.016_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib28","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2017.02.016_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S1415-47572013000300001","article-title":"Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy","volume":"36","author":"Mohseni","year":"2013","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.neuint.2017.02.016_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fnl.13.58","article-title":"Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond","volume":"9","author":"Monani","year":"2014","journal-title":"Future neurol."},{"key":"10.1016\/j.neuint.2017.02.016_bib31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s10897-016-9955-8","article-title":"A\u00a0review on spinal muscular atrophy: awareness, knowledge, and attitudes","volume":"25","author":"Moultrie","year":"2016","journal-title":"J.\u00a0Genet. Couns."},{"key":"10.1016\/j.neuint.2017.02.016_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuint.2017.02.016_bib33","doi-asserted-by":"crossref","first-page":"a000778","DOI":"10.1101\/cshperspect.a000778","article-title":"Developments in RNA splicing and disease","volume":"3","author":"Poulos","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neuint.2017.02.016_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy\u2013determining gene product, modulates axon growth and localization of \u03b2-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuint.2017.02.016_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/MCB.06077-11","article-title":"A\u00a0role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy","volume":"32","author":"Ruggiu","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuint.2017.02.016_bib38","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1261\/rna.047373.114","article-title":"Subcellular transcriptome alterations in a cell culture model of spinal muscular atrophy point to widespread defects in axonal growth and presynaptic differentiation","volume":"20","author":"Saal","year":"2014","journal-title":"Rna"},{"key":"10.1016\/j.neuint.2017.02.016_bib39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nn.2565","article-title":"Therapy development in spinal muscular atrophy","volume":"13","author":"Sendtner","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuint.2017.02.016_bib40","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1039\/C3CC46067C","article-title":"Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry","volume":"49","author":"Shabanpoor","year":"2013","journal-title":"Chem. Commun. (Camb)"},{"key":"10.1016\/j.neuint.2017.02.016_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/nar\/gku1256","article-title":"Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy","volume":"43","author":"Shabanpoor","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuint.2017.02.016_bib42","doi-asserted-by":"crossref","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.neuint.2017.02.016_bib43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.ejhg.5201821","article-title":"Population screening and cascade testing for carriers of SMA","volume":"15","author":"Smith","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuint.2017.02.016_bib44","first-page":"215","article-title":"Morpholinos andPNAs compared","volume":"10","author":"Summerton","year":"2004","journal-title":"LettPepSci"},{"key":"10.1016\/j.neuint.2017.02.016_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2017.02.016_bib46","doi-asserted-by":"crossref","first-page":"C101","DOI":"10.1152\/ajpcell.00344.2015","article-title":"Valproic acid attenuates skeletal muscle wasting by inhibiting C\/EBPbeta-regulated Atrogin1 expression in cancer cachexia","volume":"311","author":"Sun","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.neuint.2017.02.016_bib47","doi-asserted-by":"crossref","first-page":"34635","DOI":"10.1038\/srep34635","article-title":"Survival Motor Neuron (SMN) protein is required for normal mouse liver development","volume":"6","author":"Szunyogova","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuint.2017.02.016_bib48","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","article-title":"Disease mechanisms and therapeutic approaches in spinal muscular atrophy","volume":"35","author":"Tisdale","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuint.2017.02.016_bib49","doi-asserted-by":"crossref","first-page":"456478","DOI":"10.1155\/2012\/456478","article-title":"Therapy development for spinal muscular atrophy in SMN independent targets","volume":"2012","author":"Tsai","year":"2012","journal-title":"Neural Plast."},{"key":"10.1016\/j.neuint.2017.02.016_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.12813","article-title":"Developing therapies for spinal muscular atrophy","volume":"1366","author":"Wertz","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuint.2017.02.016_bib51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.stemcr.2015.02.010","article-title":"Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs","volume":"4","author":"Yoshida","year":"2015","journal-title":"Stem Cell Rep."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018617300359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018617300359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T19:31:02Z","timestamp":1589743862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018617300359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":51,"alternative-id":["S0197018617300359"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2017.02.016","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2017.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}